Loading...
•
Dec 31, 2021
Bristol-Myers Squibb Q4 2021 Earnings Report
Reported strong sales driven by robust commercial execution and significant advancement of the company’s pipeline.
Key Takeaways
Bristol Myers Squibb reported Q4 2021 revenues of $12.0 billion, an increase of 8%, driven by Eliquis, Immuno-Oncology and new product portfolios. The company posted earnings per share of $1.07 and non-GAAP EPS of $1.83.
Fourth Quarter revenues of $12.0 Billion; Full-Year Revenues of $46.4 Billion
Fourth Quarter Earnings Per Share of $1.07 and Non-GAAP EPS of $1.83; Full- Year Earnings Per Share of $3.12 and Non-GAAP EPS of $7.51
Delivered Strong Revenues for Eliquis, Immuno-Oncology and New Product Portfolios
Announced $15 Billion Share Repurchase Authorization; $5 Billion Accelerated Share Repurchase Agreement to be Executed During the First Quarter 2022
Bristol-Myers Squibb
Bristol-Myers Squibb
Bristol-Myers Squibb Revenue by Segment
Bristol-Myers Squibb Revenue by Geographic Location
Revenue by Segment
Net Product Sales Revenue
CapyFin.comAlliance and Other Revenues Revenue
CapyFin.comRevenue by Geographic Location
U.S. Revenue
CapyFin.com Forward Guidance
Bristol Myers Squibb is introducing its 2022 GAAP EPS guidance range of $3.37 - $3.67 and reaffirming its non-GAAP EPS guidance range of $7.65 - $7.95. Both GAAP and non-GAAP guidance assume current exchange rates.
Positive Outlook
- Worldwide revenues are expected to be approximately $47 billion, representing an increase in the low-single digits.
- Our Continuing Business, which represents in-line products and new product portfolio, is expected to grow in the low-double digits and contribute approximately $36.5 billion in 2022.
- Gross margin is expected to be approximately 78% for GAAP and for non-GAAP.
- Operating expenses, consisting of marketing, selling and administrative expenses and research and development expenses, are expected to decrease by approximately 10% for GAAP and be in-line with 2021 levels for non-GAAP.
- An effective tax rate of approximately 24% for GAAP and approximately 16.5% for non-GAAP.
Challenges Ahead
- Sales from key loss of exclusivity (LOE) brands, which represent Revlimid and Abraxane® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound), are expected to be approximately $10.5 billion.
- Revlimid sales are expected to be $9.5-$10 billion.
- The 2022 financial guidance excludes the impact of any potential future strategic acquisitions and divestitures, and any specified items that have not yet been identified and quantified.
- The financial guidance is subject to risks and uncertainties applicable to all forward-looking statements as described elsewhere in this press release.
- There is no reliable or reasonably estimable comparable GAAP measures for this non-GAAP financial guidance.
Revenue & Expenses
Visualization of income flow from segment revenue to net income